Do mutational targets in solid tumors change over time, and does this justify multiple biopsies and repeat NGS-based profiling in the case of progressive disease to identify new drivers?

Do mutational targets in solid tumors change over time, and does this justify multiple biopsies and repeat NGS-based profiling in the case of progressive disease to identify new drivers?

Do mutational targets in solid tumors change over time, and does this justify multiple biopsies and repeat NGS-based profiling in the case of progressive disease to identify new drivers that may have treatment implications?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lia Tsimberidou, MD, PhD

Lia Tsimberidou, MD, PhD

Tenured Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX